Injectable drug recalled due to lack of sterility assurance
Northern VA Compounders PLLC recalls compounded injectable QuadMix Super 001 (56 vials) nationwide due to lack of assurance of sterility. Affected lot #11162022@7, expiration 12/31/2022.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a compounded injectable medication with lack of assurance of sterility. No illnesses or injuries have been reported. The lack of sterility assurance for injectable medications that enter the bloodstream directly represents a significant risk of harm from potential infection, meeting the rubric criterion for 'risk-of-harm products where injury has not yet been reported' (Score 3).
Plain-English summary
QuadMix Super 001 (PGE1/Papaverine HCl/Phentolamine Mesylate/Atropine 40mcg/30mg/2mg/0.4mg/mL) is a compounded injectable medication in 2.5 mL multiple-dose vials. It was compounded by Akina Pharmacy in Sterling, Virginia and distributed by Northern VA Compounders PLLC.
Northern VA Compounders PLLC has initiated a nationwide recall of 56 vials (Lot #11162022@7, Expiration 12/31/2022) due to lack of assurance of sterility. The sterility of the injectable product cannot be confirmed to meet required safety standards.
Injectable medications must be sterile to prevent infection. For compounded drugs, the manufacturer must verify that the preparation process and controls ensure sterility. This recall indicates such verification could not be provided.
Patients who have received this product should consult their healthcare provider or pharmacist immediately. Healthcare providers should discontinue use of affected vials and contact patients who may have received doses from this lot.
The recalled product
- Product
- QuadMix Super 001 (PGE1/Papaverine HCl/Phentolamine Mesylate/Atropine) 40mcg/30mg/2mg/0.4mg/mL INJECTABLE, packaged in 2.5 mL Multiple-Dose vials, Rx Only, Compounded by: Akina Pharmacy, 23475 Rock Haven Way Suite 105, Sterling, VA 20166.
- Manufacturer
- Northern VA Compounders PLLC
- Category
- Drug — Compounded Injection
- Affected units
- 56
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 11162022@7
- Exp 12/31/2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 25 recalled by Northern VA Compounders PLLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 25 products in this recall →Related recalls
Same manufacturer · Northern VA Compounders PLLC
See all →- HighQuadMix Plus Injectable Medication Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-01-18
- HighTriMix Injection Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2023-01-18
- HighTriMix Injectable Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-01-18
- HighTriMix Plus 002 Injectable Medication Recalled for Sterility Concerns
FDA (Drugs) · 2023-01-18
- HighCompounded Injectable Medication Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-01-18
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15